Studies lung bacteria and inflammation in early COPD in smokers
Compares airway bacteria and inflammation in smokers with and without early COPD.
Plain-language title generated from the registry record
Registry title: Lung Microbiome and Inflammation in Early COPD
Key facts
- Where
- New York, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT02777879, who can take part
Where in United States
- New York University School of MedicineNew York, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- NYU Langone Health
- Trial code
- NCT02777879
- Record updated
- 28 January 2026
- Original description
This is a cross sectional case controlled study to assess lung microbiome and inflammation in smokers with and without Chronic Obstructive Pulmonary Disease (COPD). Investigators will look at active bacterial metabolic pathways in the lower airways using metagenomic and metabolomic approaches an assess relationships among microbiome, metagenome, metabolome and host immune responses in COPD and controls. Investigators believe COPD cases will have higher prevalence of pneumotype supraglottic predominant taxa (SPT) than matched controls.Read full original descriptionShow less
Lung Microbiome and Inflammation in Early Chronic Obstructive Pulmonary Disease (COPD)
This is a cross sectional case controlled study to assess lung microbiome and inflammation in smokers with and without Chronic Obstructive Pulmonary Disease (COPD). Investigators will look at active bacterial metabolic pathways in the lower airways using metagenomic and metabolomic approaches an assess relationships among microbiome, metagenome, metabolome and host immune responses in COPD and controls. Investigators believe COPD cases will have higher prevalence of pneumotype supraglottic predominant taxa (SPT) than matched controls.
Inclusion: Case definition: Smokers (>20 pack-year) with airflow obstruction (FEV1/FVC<70) and FEV1>50% predicted (early COPD GOLD 1 or 2); Control definition: Smokers with normal spirometry will serve as controls.
Exclusion: Antibiotic use within the prior 2months; Significant cardiovascular disease defined as abnormal EKG, known or suspected coronary artery disease or congestive heart failure; Diabetes mellitus; Significant liver or renal disease; Severe coagulopathy (INR > 1.4, PTT > 40 seconds and platelet count < 150x103 cells); FEV1 < 50% NOT 70; Pregnancy; ETOH use of more than >6 beers or >4 mixed drinks daily; Lack of capacity to provide informed consent.